YKST04

YKST04 is a preclinical-stage bispecific antibody being developed by Excyte Biopharma for the treatment of hepatocellular carcinoma (HCC). Developed using Excyte's proprietary multi-specific antibody platform, YKST04 is designed to target liver cancer cells. While the specific molecular targets for this program have not been publicly disclosed, the company's broader pipeline focuses on T-cell engaging bispecific antibodies that typically incorporate a CD3-binding domain to recruit and activate T-cells against tumor-associated antigens. As of early 2024, the program remains in the early stages of preclinical development.